(Sharecast News) - Ondine Biomedical announced on Thursday that the University of Ottawa Heart Institute (OHI) had adopted its Steriwave nasal photodisinfection therapy as a standard of care for all cardiac surgeries, marking a major institutional endorsement of the infection prevention technology.
OHI, the largest cardiac care centre in Canada and a globally-recognised leader in cardiovascular treatment and research, was integrating Steriwave into its pre-surgical protocols to enhance patient safety.

The AIM-traded firm said the adoption followed successful deployments at other leading institutions, including Vancouver General Hospital and the University of Alberta Hospital.

Steriwave is a light-based nasal decolonisation therapy designed to reduce surgical site infections.

Ondine said clinical use of the technology had shown meaningful reductions in infection rates, further validating its role in hospital infection control strategies.

The company said it was continuing to expand its footprint across Canada and the UK as hospitals seek innovative solutions to combat healthcare-associated infections.

"We are extremely pleased to be supporting the Ottawa Heart Institute's efforts to address multidrug resistance and enhance their patient protection protocols," said chief executive officer Carolyn Cross.

"By adopting Steriwave as standard of care, OHI is once again demonstrating its leadership in clinical excellence and its commitment to staying at the forefront of infection prevention.

"We are honoured to partner with such a forward-thinking institution, and we look forward to supporting OHI as they continue to set new benchmarks in patient protection and antimicrobial stewardship."

At 1045 BST, shares in Ondine Biomedical were up 11.76% at 9.5p.

Reporting by Josh White for Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE